[Corrigendum] Survival outcomes in patients with T3‑4aN0M0 glottic laryngeal squamous cell carcinoma and evaluation of postoperative radiotherapy
Jian Zhou, Yu Heng, Yue Yang, Xiaoke Zhu, Liang Zhou, Hongli Gong, Chengzhi Xu, Lei Tao
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHead and Neck Cancer Studies
Oncol Lett 24: 434, 2022; DOI: 10.3892/ol.2022.13554
Following the publication of this article, the authors have realized that an incorrect description of the treatment protocol was reported in the “Postoperative procedures” subsection of the “Materials and methods” on p. 2 concerning the three regimens on which platinum-based chemoradiotherapy (CRT) was based. The sentence commencing on line 15 of this section should have read as follows (changes are highlighted in bold): “[Platinum-based concurrent CRT was performed based on one of three regimens: i) cisplatin (DDP) regimen-DDP [75 mg/m^2^ (not “45–50 mg/m^2^/day”)] on days 1–3; ii) DDP combined with 5-fluorouracil (5-FU) (PF regimen)-DDP [75 mg/m^2^ (not “40 mg/m^2^/day”)] on days 1–3 and 5-FU [650–700 mg/m^2^ (not 750–800 mg/m^2^/day)] on days 1–4 (not days 1–5); or iii) carboplatin (CBP) regimen-CBP (AUC=5) on days 1–2 [not, as was reported, “carboplatin (CBP)-based regimen-CBP, calcium folinate, and tegafur (200, 300, or 1,000 mg/m^2^/day, respectively) on days 1–3 for 1–2 cycles].
The authors regret that this misinformation was reported in the text, and thank the Editor of Oncology Letters for allowing them the opportunity to publish this Corrigendum.